Historique
Bulletin de Périodique
Drug and Alcohol Review , Vol.30, n°3 - May 2011 - Pharmaceuticals
Auteur(s) :
NIELSEN, S. (Éditeur scientifique) ;
BRUNO, R. (Éditeur scientifique)
Paru le :
01/05/2011
Année
2011
Page(s) :
233-333
Langue(s) :
Anglais
Domaine :
Autres substances / Other substances ; Drogues illicites / Illicit drugs
Note de contenu :
CONTENTS:
• Pharmaceutical drugs: the delicate balance between reducing pain and reducing harm. Nielsen S., Bruno R., p. 233-235.
• Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Larance B., Degenhardt L., Lintzeris N., Winstock A., Mattick R., p. 236-245.
• The availability, diversion and injection of pharmaceutical opioids in South Asia. Larance B., Ambekar A., Azim T., Murthy P., Panda S., Degenhardt L., et al., p. 246-254.
• Recent trends in pharmaceutical drug use among frequent injecting drug users, frequent methamphetamine users and frequent ecstasy users in New Zealand, 2006-2009. Wilkins C., Sweetsur P., Griffiths R., p. 255-263.
• The prescription drug epidemic in the United States: a perfect storm. Maxwell J.C., p. 264-270.
• Trends over time in characteristics of pharmaceutical drug-related ambulance attendances in Melbourne. Lloyd B.K., McElwee P.R., p. 271-280.
• Benzodiazepines, opioids and driving: an overview of the experimental research. Leung S.Y., p. 281-286.
• Reducing harm from injecting pharmaceutical tablet or capsule material by injecting drug users. Roux P., Carrieri M.P., Keijzer L., Dasgupta N., p. 287-290.
• Pharmaceutical opioid analgesic and heroin dependence: how do treatment-seeking clients differ in Australia? Nielsen S., Bruno R., Lintzeris N., Fischer J., Carruthers S., Stoove M., p. 291-299.
• Prescription opioid abuse, pain and addiction: clinical issues and implications. Ling W., Mooney L., Hillhouse M., p. 300-305.
• Acceptability of cognitive-behaviour therapy via the Internet for cessation of benzodiazepine use. Parr J.M., Kavanagh D.J., Young R.M., Mitchell G., p. 306-314.
• Increasing the benefits and reducing the harms of prescription opioid analgesics. Hallinan R., Osborn M., Cohen M., Dobbin M., Wodak A., p. 315-323.
• Managing the continuum between pain and dependency in general practice. Holliday S.M., p. 324-326.
• Decreasing the harms of prescription opioids: a case for pharmacists. Sproule B.A., p. 327-329.
• A harm reductionist response. Brogan D., Kelsall J., p. 330-331.
• Harms: How much, how many, how often? Dunlop A., p. 332-333.
• Pharmaceutical drugs: the delicate balance between reducing pain and reducing harm. Nielsen S., Bruno R., p. 233-235.
• Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Larance B., Degenhardt L., Lintzeris N., Winstock A., Mattick R., p. 236-245.
• The availability, diversion and injection of pharmaceutical opioids in South Asia. Larance B., Ambekar A., Azim T., Murthy P., Panda S., Degenhardt L., et al., p. 246-254.
• Recent trends in pharmaceutical drug use among frequent injecting drug users, frequent methamphetamine users and frequent ecstasy users in New Zealand, 2006-2009. Wilkins C., Sweetsur P., Griffiths R., p. 255-263.
• The prescription drug epidemic in the United States: a perfect storm. Maxwell J.C., p. 264-270.
• Trends over time in characteristics of pharmaceutical drug-related ambulance attendances in Melbourne. Lloyd B.K., McElwee P.R., p. 271-280.
• Benzodiazepines, opioids and driving: an overview of the experimental research. Leung S.Y., p. 281-286.
• Reducing harm from injecting pharmaceutical tablet or capsule material by injecting drug users. Roux P., Carrieri M.P., Keijzer L., Dasgupta N., p. 287-290.
• Pharmaceutical opioid analgesic and heroin dependence: how do treatment-seeking clients differ in Australia? Nielsen S., Bruno R., Lintzeris N., Fischer J., Carruthers S., Stoove M., p. 291-299.
• Prescription opioid abuse, pain and addiction: clinical issues and implications. Ling W., Mooney L., Hillhouse M., p. 300-305.
• Acceptability of cognitive-behaviour therapy via the Internet for cessation of benzodiazepine use. Parr J.M., Kavanagh D.J., Young R.M., Mitchell G., p. 306-314.
• Increasing the benefits and reducing the harms of prescription opioid analgesics. Hallinan R., Osborn M., Cohen M., Dobbin M., Wodak A., p. 315-323.
• Managing the continuum between pain and dependency in general practice. Holliday S.M., p. 324-326.
• Decreasing the harms of prescription opioids: a case for pharmacists. Sproule B.A., p. 327-329.
• A harm reductionist response. Brogan D., Kelsall J., p. 330-331.
• Harms: How much, how many, how often? Dunlop A., p. 332-333.
Affiliation :
Australia
Dépouillements
Ajouter le résultat à votre sélection
B. LARANCE ;
L. DEGENHARDT ;
N. LINTZERIS ;
A. WINSTOCK ;
R. MATTICK
|
2011
Dans Drug and Alcohol Review (Vol.30, n°3, May 2011) Article : Périodique
Dans Drug and Alcohol Review (Vol.30, n°3, May 2011) Article : Périodique
AIMS: This paper (i) reviews the language used to describe and manage those patient practices that fall outside standard medical models of opioid treatment (for pain and opioid dependence), and (ii) proposes a consistent terminology that can be [...]
INTRODUCTION AND AIMS: Abuse of prescription analgesics in the USA is increasing. The epidemic has been driven by many factors, including marketing strategies, incorrect prescribing practices, a variety of legal and illegal drug sources, belated[...]
ISSUES: Road crashes contribute significantly to the total burden of injury in Australia, with the risk of injury being associated with the presence of drugs and/or alcohol in the driver's blood. Increasingly, some of the most commonly detected [...]
P. ROUX ;
M. P. CARRIERI ;
L. KEIJZER ;
N. DASGUPTA
|
2011
Dans Drug and Alcohol Review (Vol.30, n°3, May 2011) Article : Périodique
Dans Drug and Alcohol Review (Vol.30, n°3, May 2011) Article : Périodique
BACKGROUND: It has long been known that drug users may use a variety of pharmaceutical preparations by injection, many of which are not intended for intravenous administration (e.g. buprenorphine, methylphenidate, oxycodone). The introduction of[...]